Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

Key Inclusion Criteria: 1. Provide written informed consent prior to performing study procedures 2. Hospitalized. 3. Male or female ≥18 years of age 4. Positive for severe acute respiratory syndrome coronavirus 2 5. Presence of symptoms of lower respiratory tract infection (LRTI) including at least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, or more significant lower respiratory tract symptoms, including shortness of breath 6. At least 1 of the following: respiratory rate (RR) ≥20 breaths per minute, room air oxygen saturation (SpO2) \<98%, requirement for supplemental oxygen, heart rate (HR) ≥90 beats per minute, or temperature \>38.3°C 7. Women of childbearing potential must agree to abstinent or use at least 1 form of contraception not including hormonal contraception from the day of screening through Day 30 Key Exclusion Criteria: 1. Hospitalized but no longer requires ongoing inpatient care (i.e., discharge is anticipated in ≤24 hours) 2. Patient is not anticipated to survive \>48 hours OR is under palliative care 3. Evidence of critical illness, defined by at least 1 of the following: * Respiratory failure requiring at least 1 of the following: 1. Endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula 2. Noninvasive positive pressure ventilation (NIPVV), OR 3. Extracorporeal membrane oxygenation (ECMO) or clinical diagnosis of respiratory failure * Shock (defined by systolic blood pressure (BP) \<90 mm Hg, or diastolic blood pressure (BP) \<60 mm Hg or requiring vasopressors), OR * Multi-organ dysfunction/failure 4. Severe central nervous system (CNS) conditions 5. Chronic kidney disease requiring dialysis 6. Known allergy to the study drug or salicylate containing medications. 7. Suspected and/or confirmed pregnancy or breastfeeding 8. Current or planned participation in any other clinical trial of a treatment being developed under a US investigational new drug (IND) or emergency use authorization (EUA). 9. Patients receiving chemotherapeutic agents and/or immunomodulators (including monoclonal antibodies (Mabs) or plasma transfusions) for chronic disease conditions.